Research and development Driving scientific innovation to deliver the next generation of transformational medicines and vaccines for patients
Read morePress releases
- ViiV Healthcare submits New Drug Application to the FDA for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
- ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention
- Nucala (mepolizumab) is the first treatment to show a significant reduction in flares for patients with Hypereosinophilic Syndrome (HES)
Tweets from GSK
-
GSK @GSK
We’re working to develop truly transformational medicines that can improve and extend the lives of patients. Learn more #BehindTheScience gsk.com/en-gb/behind-t…
about 56 minutes ago
-
GSK @GSK
Approximately how many new cases of multiple #myeloma were diagnosed globally in 2018? #ASH19
about 2 hours ago -
GSK @GSK
Multiple #myeloma causes the highest number of patient deaths in blood cancers. Find out why this is the case as @IreneGhobrial, Professor of Medicine at @DanaFarber @harvardmed explains…#ASH19
about 4 hours ago
